<SEC-DOCUMENT>0001096906-23-000901.txt : 20230425
<SEC-HEADER>0001096906-23-000901.hdr.sgml : 20230425
<ACCEPTANCE-DATETIME>20230425160149
ACCESSION NUMBER:		0001096906-23-000901
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230425
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230425
DATE AS OF CHANGE:		20230425

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UTAH MEDICAL PRODUCTS INC
		CENTRAL INDEX KEY:			0000706698
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				870342734
		STATE OF INCORPORATION:			UT
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12575
		FILM NUMBER:		23844778

	BUSINESS ADDRESS:	
		STREET 1:		7043 S 300 WEST
		CITY:			MIDVALE
		STATE:			UT
		ZIP:			84047
		BUSINESS PHONE:		8015661200
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>utmd-20230425.htm
<DESCRIPTION>UTAH MEDICAL PRODUCTS, INC. - FORM 8-K SEC FILING
<TEXT>
<XBRL>
<?xml version='1.0' encoding='us-ascii' standalone='no'?>
<html xmlns='http://www.w3.org/1999/xhtml' xmlns:xbrli='http://www.xbrl.org/2003/instance' xmlns:dei='http://xbrl.sec.gov/dei/2022q4' xmlns:i='http://www.xbrl.org/2003/instance' xmlns:xbrldi='http://xbrl.org/2006/xbrldi' xmlns:iso4217='http://www.xbrl.org/2003/iso4217' xmlns:ix='http://www.xbrl.org/2013/inlineXBRL' xmlns:ixt='http://www.xbrl.org/inlineXBRL/transformation/2015-02-26' xmlns:ixt-sec='http://www.sec.gov/inlineXBRL/transformation/2015-08-31' xmlns:utr='http://www.xbrl.org/2009/utr' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance'>
<head>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD9NVDXT]. www.edgarsuite.com -->
<title>UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing</title>
<meta content='text/html; charset=UTF-8' http-equiv='Content-Type' />
</head>
<body>
<div style='display:none'>
<ix:header>
<ix:hidden>
<ix:nonNumeric name='dei:EntityCentralIndexKey' contextRef='D230425' id='fact1'>0000706698</ix:nonNumeric>
<ix:nonNumeric name='dei:AmendmentFlag' contextRef='D230425' id='fact2'>false</ix:nonNumeric>
</ix:hidden>
<ix:references>
<link:schemaRef xlink:arcrole='http://www.xbrl.org/2003/linkbase' xlink:href='utmd-20230425.xsd' xlink:type='simple'/>
</ix:references>
<ix:resources>
<i:context id='D230425'>
<i:entity>
<i:identifier scheme='http://www.sec.gov/CIK'>0000706698</i:identifier>
</i:entity>
<i:period>
<i:startDate>2023-04-25</i:startDate>
<i:endDate>2023-04-25</i:endDate>
</i:period>
</i:context>
</ix:resources>
</ix:header>
</div>
<div style='margin-left:72pt;width:468pt'><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:14pt Times New Roman;margin:0;text-align:center'><b>UNITED STATES </b></p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style='font:15pt Times New Roman;margin:0;text-align:center'><b>Washington, D.C. &#160;20549</b></p>
<p style='font:15pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'><span style='font-size:14pt'><b>FORM </b><b><ix:nonNumeric name='dei:DocumentType' contextRef='D230425' escape='true'>8-K</ix:nonNumeric></b></span></p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'><b>CURRENT REPORT</b></p>
<p style='font:14pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:12pt Times New Roman;margin:0;text-align:center'><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>Date of Report (date of earliest event reported): &#160;<ix:nonNumeric name='dei:DocumentPeriodEndDate' contextRef='D230425' format='ixt:datemonthdayyearen'>April 25, 2023</ix:nonNumeric></p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;margin-right:72pt;text-align:justify'>&#160;</p>
<table style='border-collapse:collapse;width:468pt'><tr><td colspan='5' valign='top' style='width:468pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:14pt Times New Roman;margin:0;text-align:center'><b><ix:nonNumeric name='dei:EntityRegistrantName' contextRef='D230425' escape='true'>UTAH MEDICAL PRODUCTS, INC.</ix:nonNumeric></b></p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:468pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Exact name of registrant as specified in its charter)</p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:11pt'><b><ix:nonNumeric name='dei:EntityIncorporationStateCountryCode' contextRef='D230425' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric></b></span></p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'><b><ix:nonNumeric name='dei:EntityFileNumber' contextRef='D230425' escape='true'>000-12575</ix:nonNumeric></b></p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:11pt'><b><ix:nonNumeric name='dei:EntityTaxIdentificationNumber' contextRef='D230425' escape='true'>87-0342734</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(State or other jurisdiction of</p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Commission File Number)</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(IRS Employer</p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>incorporation or organization)</p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>Identification No.)</p>
</td></tr>
<tr><td valign='top' style='width:147.95pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.15pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b><ix:nonNumeric name='dei:EntityAddressAddressLine1' contextRef='D230425' escape='true'>7043 South 300 West</ix:nonNumeric></b></span></p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b><ix:nonNumeric name='dei:EntityAddressCityOrTown' contextRef='D230425' escape='true'>Midvale</ix:nonNumeric></b><b>, </b><b><ix:nonNumeric name='dei:EntityAddressStateOrProvince' contextRef='D230425' format='ixt-sec:stateprovnameen'>Utah</ix:nonNumeric></b></span></p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b><ix:nonNumeric name='dei:EntityAddressPostalZipCode' contextRef='D230425' escape='true'>84047</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Address of principal executive offices)</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Zip code)</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:11pt Times New Roman;margin:0'>Registrant&#8217;s telephone number, including area code: &#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:10pt Times New Roman;margin:0;text-align:center'><span style='font-size:12pt'><b>Phone: </b><b>(</b><b><ix:nonNumeric name='dei:CityAreaCode' contextRef='D230425' escape='true'>801</ix:nonNumeric></b><b>) </b><b><ix:nonNumeric name='dei:LocalPhoneNumber' contextRef='D230425' escape='true'>566-1200</ix:nonNumeric></b></span></p>
</td></tr>
<tr><td colspan='3' valign='top' style='width:308pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.1pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:147.9pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:468pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:12pt Times New Roman;margin:0;text-align:center'><b>n/a</b></p>
</td></tr>
<tr><td colspan='5' valign='top' style='width:468pt;padding-left:0.7pt;padding-right:0.7pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>(Former name or former address, if changed since last report)</p>
</td></tr>
</table>
<p style='font:11pt Times New Roman;margin:0;margin-right:72pt;text-align:justify'>&#160;</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>
<p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</div>
<div style='margin-left:72pt'><table style='border-collapse:collapse'><tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:WrittenCommunications' contextRef='D230425' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:SolicitingMaterial' contextRef='D230425' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:PreCommencementTenderOffer' contextRef='D230425' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'><ix:nonNumeric name='dei:PreCommencementIssuerTenderOffer' contextRef='D230425' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:478.8pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).</p>
</td></tr>
<tr><td valign='top' style='width:27.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:450.9pt'><p style='font:10pt Times New Roman;margin:0;text-align:right'>Emerging growth company <ix:nonNumeric name='dei:EntityEmergingGrowthCompany' contextRef='D230425' format='ixt-sec:boolballotbox'>&#9744;</ix:nonNumeric></p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:478.8pt'><p style='font:10pt Times New Roman;margin:0'>&#160;</p>
</td></tr>
<tr><td colspan='2' valign='top' style='width:478.8pt'><p style='font:10pt Times New Roman;margin:0'>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [&#160;&#160;]</p>
</td></tr>
</table>
</div>
<div style='margin-left:72pt;width:468pt'><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><hr style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'/><p style='line-height:0;margin:0'></p>
<hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/><p style='font:11pt Times New Roman;margin:0'><b>ITEM 2.02&#8212;RESULTS OF OPERATIONS AND FINANCIAL CONDITION</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:12pt Times New Roman;margin:0;margin-left:90pt'>Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three months ended March 31, 2023 and forward-looking statements relating to 2023 and beyond as presented in a press release dated April 25, 2023. &#160;</p>
<p style='font:12pt Times New Roman;margin:0;margin-left:90pt'>&#160;</p>
<p style='font:12pt Times New Roman;margin:0;margin-left:90pt'>The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.</p>
<p style='font:12pt Times New Roman;margin:0;margin-left:90pt'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0'><b>ITEM 9.01&#8212;FINANCIAL STATEMENTS AND EXHIBITS</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>The following is filed as an exhibit to this report: &#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</div>
<div style='margin-left:72pt'><table style='border-collapse:collapse;width:476pt'><tr><td valign='top' style='width:59.75pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Exhibit</b></p>
<p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Number*</b></p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:329.5pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Title of Document</b></p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:61.75pt;padding-left:5.75pt;padding-right:5.75pt;border-bottom:0.5pt solid #000000'><p style='font:9pt Times New Roman;margin:0;text-align:center'>&#160;</p>
<p style='font:9pt Times New Roman;margin:0;text-align:center'><b>Location</b></p>
</td></tr>
<tr><td valign='top' style='width:59.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'><b>Item 99.1</b></p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:329.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'><span style='font-size:12pt;color:#0000FF;border-bottom:1px solid #0000FF'><a href='utmd_ex99z1.htm' style='text-decoration:none'>Financial information for Utah Medical Products, Inc. for the three months ended March 31, 2023 and forward-looking statements relating to 2023 and beyond as presented in a press release dated March 31, 2023</a></span><span style='font-size:12pt'>.</span></p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:61.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:59.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:329.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:61.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>This filing</p>
</td></tr>
<tr><td valign='top' style='width:59.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:center'>&#160;</p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:329.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0'>&#160;</p>
</td><td valign='top' style='width:12.5pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:61.75pt;padding-left:5.75pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
</table>
</div>
<div style='margin-left:72pt;width:468pt'><p style='font:11pt Times New Roman;margin:0;text-indent:-18pt;margin-left:18pt;text-align:justify'>_______________________________________</p>
<p style='font:9pt Times New Roman;margin-top:6pt;margin-bottom:0pt;margin-left:18pt;text-align:justify'><kbd style='position:absolute;font:9pt Times New Roman;margin-left:-18pt'>*</kbd>All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document. &#160;</p>
<p style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt;text-indent:-18pt;margin-left:18pt;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:center'><b>SIGNATURES</b></p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</div>
<div style='margin-left:72pt'><table style='border-collapse:collapse'><tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'><b>UTAH MEDICAL PRODUCTS, INC.</b></p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td colspan='2' valign='top' style='width:244.75pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>Dated:  April 25, 2023</p>
</td><td valign='top' style='width:26.7pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>By:</p>
</td><td valign='top' style='width:218.05pt;border-bottom:0.5pt solid #000000'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>/s/ Kevin L. Cornwell</p>
</td></tr>
<tr><td valign='top' style='width:234.05pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:26.7pt;padding-left:0.7pt;padding-right:5.75pt'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>&#160;</p>
</td><td valign='top' style='width:218.05pt;border-top:0.5pt solid #000000'><p style='font:11pt Times New Roman;margin:0;text-align:justify'>Kevin L. Cornwell, Chief Executive Officer</p>
</td></tr>
</table>
</div>
<div style='margin-left:72pt;width:468pt'><hr style='border:0;height:0;width:0;margin:14pt 0 0 0'/></div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>utmd_ex99z1.htm
<DESCRIPTION>FINANCIAL INFORMATION
<TEXT>
<HTML>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD9NVDXT]. www.edgarsuite.com -->
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<DIV style=margin-left:72pt;width:468pt><HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:10pt Times New Roman;margin:0;margin-right:-6.5pt'><FONT style=font-size:11pt><B>EXHIBIT 99.1</B></FONT><B> </B></P>
<P align=center style='font:10pt Times New Roman;margin:0'>&nbsp;</P>
<P align=center style='font:10pt Times New Roman;margin:0;margin-right:-6.3pt'><B>Utah Medical Products, Inc. Reports Financial Performance for First Quarter 2023</B></P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:0pt'>Contact: Brian Koopman (801) 566-1200</KBD><KBD style=margin-left:396pt></KBD>April 25, 2023&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Salt Lake City, Utah &#8211;&nbsp;In the first calendar quarter (1Q) of 2023, Utah Medical Products, Inc. (Nasdaq: UTMD) attained financial results consistent with achieving its goals previously announced for calendar year 2023. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Summary of results</FONT>.</P>
<P style='font:11pt Times New Roman;margin:0'>The following is a summary comparison of 1Q 2023 with 1Q 2022 income statement measures:</P>
<TABLE style=border-collapse:collapse;width:212.65pt;margin-left:40.85pt><TR><TD valign=top style=background-color:#D3F0FE;width:122.05pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Revenues (Sales):</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:90.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>+ 1.6%</P>
</TD></TR>
<TR><TD valign=top style=width:122.05pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit (GP):</P>
</TD><TD valign=top style=width:90.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> + 4.1%</P>
</TD></TR>
<TR><TD valign=top style=background-color:#D3F0FE;width:122.05pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income (OI):</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:90.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'> &nbsp;&nbsp;( 1.9%)</P>
</TD></TR>
<TR><TD valign=top style=width:122.05pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Net Income (NI):</P>
</TD><TD valign=top style=width:90.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>+19.2%</P>
</TD></TR>
<TR><TD valign=top style=background-color:#D3F0FE;width:122.05pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Earnings Per Share (EPS):</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:90.6pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>+20.2%</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Profit margins in 1Q 2023 compared to 1Q 2022 follow:</P>
<TABLE style=border-collapse:collapse;width:432.35pt;margin-left:5.4pt><TR><TD valign=top style=width:262.25pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>&nbsp;</P>
</TD><TD valign=top style=width:85.05pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>1Q 2023 </P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'><FONT style='border-bottom:1px solid #000000'>(JAN &#8211;&nbsp;MAR)</FONT></P>
</TD><TD valign=top style=width:85.05pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>1Q 2022 </P>
<P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'><FONT style='border-bottom:1px solid #000000'>(JAN &#8211;&nbsp;MAR)</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#D3F0FE;width:262.25pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Gross Profit Margin (gross profits/ sales):</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:85.05pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>62.6%</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:85.05pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>61.1%</P>
</TD></TR>
<TR><TD valign=top style=width:262.25pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>Operating Income Margin (operating income/ sales):</P>
</TD><TD valign=top style=width:85.05pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>35.5%</P>
</TD><TD valign=top style=width:85.05pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>36.7%</P>
</TD></TR>
<TR><TD valign=top style=background-color:#D3F0FE;width:262.25pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>EBT Margin (profits before income taxes/ sales):</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:85.05pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>40.9%</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:85.05pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>36.8%</P>
</TD></TR>
<TR><TD valign=top style=width:262.25pt><P style='font:11pt Times New Roman;margin:0;margin-right:-6.25pt'>Net Income Margin (profit after taxes/ sales):</P>
</TD><TD valign=top style=width:85.05pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>33.7% </P>
</TD><TD valign=top style=width:85.05pt><P align=center style='font:11pt Times New Roman;margin:0;margin-right:-6.3pt'>28.7% </P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; &#163;&nbsp;or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and &#8364;&nbsp;or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Domestic sales in 1Q 2023 were 10% lower, but sales outside the U.S. (OUS) were up 23% in USD terms compared to 1Q 2022. &nbsp;Using the same foreign currency exchange (FX) rates for sales not invoiced in USD, i.e. in &#8220;constant currency&#8221; terms, OUS sales were up 28%. Because 28% of consolidated USD sales were invoiced in foreign currencies, the change in FX rates for OUS sales did have an impact on period-to-period relative financial results. FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 1Q 2023 and 1Q 2022 follow:</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'><FONT style='border-bottom:1px solid #000000'>1Q 2023</FONT></KBD><KBD style=margin-left:248.1pt></KBD><FONT style='border-bottom:1px solid #000000'>1Q 2022</FONT> &nbsp;&nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>Change</FONT>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>GBP</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 1.215</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 1.339</KBD><KBD style=margin-left:297.7pt></KBD>(9.3%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>EUR</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 1.078</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 1.126</KBD><KBD style=margin-left:297.7pt></KBD>(4.2%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>AUD</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 0.685</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 0.724</KBD><KBD style=margin-left:297.7pt></KBD>(5.3%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>CAD</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 0.739</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 0.789</KBD><KBD style=margin-left:297.7pt></KBD>(6.3%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>The weighted-average negative impact on foreign currency sales was 5.9%, reducing reported USD sales by $223 relative to the same foreign currency sales in 1Q 2022. &nbsp;In constant currency terms, total consolidated 1Q 2023 sales were up $420 (+3.4%).</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Due mostly to better absorption of manufacturing overhead costs in Ireland and lower employee healthcare plan costs in the U.S., UTMD was able to increase its 1Q 2023 Gross Profit Margin (GPM), gross profits/sales, compared to 1Q 2022.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Consolidated OI in 1Q 2023 at $4,439 (35.5% of sales) was $84 lower than 1Q 2022 OI of $4,522 (36.7% of sales). &nbsp;Although UTMD&#8217;s 1Q 2023 Operating Income Margin (OIM) benefitted from higher sales, a higher GPM and a stronger USD which reduced OUS operating expenses in USD terms by $80, it suffered more from the $348 (2.8% of sales) higher litigation expenses compared to 1Q 2022. &nbsp;The $1,105 per quarter straight-line amortization of the $21,000 purchase price that UTMD paid CSI in early 2019 to acquire the remaining 4.75 years&#8217; exclusive U.S. Filshie distribution rights was 8.8% of 1Q 2023 sales </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style=font-size:11pt>compared to 9.0% of 1Q 2022 sales. The purchase price of CSI&#8217;s remaining exclusive distribution rights was recognized as an identifiable intangible asset (IIA) which will be fully amortized in October 2023. IIA amortization expense in total, including that remaining from the 2011 Femcare acquisition, which comprises a significant portion of General &amp; Administrative (G&amp;A) operating expenses, was 12.7% of 1Q 2023 consolidated sales compared to 13.3% of 1Q 2022 consolidated sales. In other words, UTMD&#8217;s OIM excluding IIA amortization and litigation expense was 51.4% in 1Q 2023 compared to 50.5% in 1Q 2022.</FONT></P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Income Before Tax (EBT) benefitted from much higher interest income on UTMD&#8217;s cash reserves. &nbsp;&nbsp;Non-operating income (NOI) in 1Q 2023, in which interest income is captured, was $681 compared to $8 in 1Q 2022. As a result of $589 higher EBT and a lower income tax provision rate due to a portion of NOI received from tax exempt interest, UTMD&#8217;s Net Income Margin (NIM) in 1Q 2023 at 33.7% was substantially higher than the 28.7% NIM in 1Q 2022. &nbsp;UTMD&#8217;s consolidated income tax provision rate in 1Q 2023 was 17.7% of EBT compared to 22.0% in 1Q 2022. The result was that 1Q 2023 NI was 19.2% higher, and 1Q 2023 Earnings Per Share were 20.2% higher, than in 1Q 2022. &nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD&#8217;s March 31, 2023 Balance Sheet, in the absence of debt, remained strong. &nbsp;Ending Cash and Investments were $80.9 million on March 31, 2023 compared to $75.1 million on December 31, 2022. Stockholders&#8217; Equity was up $3.8 million in the first three month calendar period from December 31, 2022. &nbsp;FX rates for Balance Sheet purposes are the applicable rates at the end of each reporting period. The FX rates from the applicable foreign currency to USD for assets and liabilities at the end of 1Q 2023 and the end of 1Q 2022 follow:</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'><FONT style='border-bottom:1px solid #000000'>3-31-23</FONT></KBD><KBD style=margin-left:248.1pt></KBD><FONT style='border-bottom:1px solid #000000'>3-31-22</FONT> &nbsp;&nbsp;&nbsp;<FONT style='border-bottom:1px solid #000000'>Change</FONT>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>GBP</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 1.237</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 1.315</KBD><KBD style=margin-left:297.7pt></KBD> &nbsp;(6.0%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>EUR</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 1.087</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 1.110</KBD><KBD style=margin-left:297.7pt></KBD> &nbsp;(2.0%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>AUD</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 0.670</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 0.750</KBD><KBD style=margin-left:297.7pt></KBD>(10.6%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:108pt'>CAD</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:180pt'> 0.739</KBD><KBD style='position:absolute;font:11pt Times New Roman;margin-left:248.1pt'> 0.801</KBD><KBD style=margin-left:297.7pt></KBD> &nbsp;(7.7%)&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Sales</FONT>. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>Total consolidated 1Q 2023 UTMD sales were $197 (+1.6%) higher than in 1Q 2022. Constant currency sales were $420 (+3.4%) higher. U.S. domestic sales were 10.0% lower and OUS sales were 22.9% higher despite an average 5.9% stronger USD. Because of the relatively short span of time, results for any given three-month period in comparison with a previous three month period may not be indicative of comparative results for the year as a whole. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Domestic sales in 1Q 2023 were $7,185 compared to $7,984 in 1Q 2022. &nbsp;The components of domestic sales include 1) &#8220;direct sales&#8221; of UTMD&#8217;s medical devices to user facilities (and med/surg stocking distributors for hospitals), excluding Filshie device sales, 2) &#8220;OEM sales&#8221; of components and other products manufactured by UTMD for other medical device and non-medical device companies, and 3) &#8220;Filshie device sales&#8221;, manufactured by Femcare and distributed in the U.S. by UTMD. </P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>Direct sales, representing 50% of total domestic sales, were $372 (9.3%) lower in 1Q 2023 than in 1Q 2022. &nbsp;This was due to continuing supply chain disruption, in particular independent sterilizer capacity constraints. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>OEM sales, representing 32% of total domestic sales, were $375 (+14.0%) lower. U.S. sales to UTMD&#8217;s largest OEM customer which had grown rapidly in recent years were $391 lower in 1Q 2023 compared to 1Q 2022. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:36pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>Filshie device sales were $51 (3.9%) lower in 1Q 2023 compared to 1Q 2022. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>OUS sales in 1Q 2023 were $5,335 compared to $4,339 in 1Q 2022. OUS sales invoiced in GBP, EUR, AUD and CAD currencies were reduced $223 as a result of changes in FX rates resulting from an average 5.9% stronger USD. &nbsp;In other words, constant currency OUS sales were $5,558, which was 28.1% higher than in 1Q 2022. &nbsp;The foreign currency OUS sales in 1Q 2023 were $3,558, which was 67% of OUS sales and 28% of total consolidated sales. &nbsp;Foreign currency OUS sales in 1Q 2022 were $2,906, which was 67% of OUS sales and 24% of total consolidated sales. &nbsp;&nbsp;</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Gross Profit (GP)</FONT>. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>GP results from subtracting the costs of manufacturing products, including quality assurance and freight for receiving raw materials from vendors, from revenues. UTMD&#8217;s GP was $310 (+4.1%) higher in 1Q 2023 than in 1Q 2022. &nbsp;GP increased more than revenues due primarily to two favorable period-to-period differences: better absorption of manufacturing overhead costs in Ireland as a result of production which increased more than overhead costs increased, and 2) much lower healthcare costs for U.S. employees compared to 1Q 2022 under UTMD&#8217;s self-funded plan. The Company selectively raised product prices during 1Q 2023 based on specific input costs from vendors. As another cost-of-living pay adjustment for employees becomes effective in April 2023, the Company still expects to maintain its GPM for the year as a whole consistent with 2022. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Operating Income (OI)</FONT>. </P>
<P style='font:11pt Times New Roman;margin:0'>OI results from subtracting Operating Expenses (OE) from GP. OE is comprised of G&amp;A expenses, sales and marketing (S&amp;M) expenses and product development (R&amp;D) expenses. &nbsp;Consolidated OE were $3,404 in 1Q 2023 (27.2% of sales) compared to $3,010 in 1Q 2022 (24.4% of sales). &nbsp;Ignoring the portion of OE that were litigation expenses and non-cash IIA amortization expenses, OE in 1Q 2023 were 11.2% of consolidated sales compared to 10.6% of sales in 1Q 2022. &nbsp;A stronger USD in 1Q 2023 compared to 1Q 2022 helped OI performance by reducing OUS OE in USD terms by $80, comprised of reducing IIA amortization expense by $49 and all other OUS OE by $31. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Consolidated G&amp;A expenses were $2,873 (22.9% of sales) in 1Q 2023 compared to $2,551 (20.7% of sales) in 1Q 2022. G&amp;A expenses include litigation costs which were $409 in 1Q 2023 compared to $61 in 1Q 2022. The G&amp;A expenses in 1Q 2023 included $483 (3.9% of sales) of non-cash expense from the amortization of IIA resulting from the 2011 Femcare acquisition, which were $532 (4.3% of sales) in 1Q 2022. &nbsp;The lower USD IIA amortization expense was the result of a stronger USD, as the Femcare amortization expense in GBP in 1Q 2023 was the same as in 1Q 2022. In addition, G&amp;A expenses in both periods included $1,105 IIA amortization expense resulting from the purchase of the CSI remaining U.S. exclusive Filshie distribution rights, which represented 8.8% of 1Q 2023 sales compared to 9.0% of 1Q 2022 sales. &nbsp;Excluding the litigation and non-cash IIA amortization expenses, G&amp;A expenses were $876 (7.0% of sales) in 1Q 2023 compared to $853 (6.9% of sales) in 1Q 2022. &nbsp;The change in FX rates reduced 1Q 2023 OUS G&amp;A expenses by $74, comprised of reducing IIA amortization expense by $49 and all other G&amp;A expenses by $24. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>S&amp;M expenses were $387 (3.1% of sales) in 1Q 2023 compared to $336 (2.7% of sales) in 1Q 2022. &nbsp;The change in FX rates reduced 1Q 2023 OUS S&amp;M expenses by $6. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>R&amp;D expenses in 1Q 2023 were $144 (1.1% of sales) compared to $123 (1.0% of sales) in 1Q 2022.  The change in FX rates reduced 1Q 2023 OUS R&amp;D expenses by $1. &nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>In summary, OI in 1Q 2023 was $4,439 (35.5% of sales) compared to $4,522 (36.7% of sales) in 1Q 2022. &nbsp;The lower OI Margin was due to the $348 higher litigation expenses. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Income Before Tax (EBT).</FONT> &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>EBT results from subtracting net non-operating expense (NOE) or adding net non-operating income (NOI) from or to, as applicable, OI. Consolidated 1Q 2023 EBT was $5,119 (40.9% of sales) compared to $4,530 (36.8% of sales) in 1Q 2022. The $589 (+13.0%) higher 1Q 2023 EBT compared to 1Q 2022 was the result of $673 higher NOI. NOE/NOI includes the combination of 1) expenses from loan interest and bank fees; 2) expenses or income from losses or gains from remeasuring the value of EUR cash bank balances in the UK, and GBP cash balances in Ireland, in USD terms; and 3) income from rent of underutilized property, investment income and royalties received from licensing the Company&#8217;s technology. NOI in 1Q 2023 included $646 higher interest income on UTMD&#8217;s cash balances. &nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>The EBT of Utah Medical Products, Inc. in the U.S. was $2,562 in 1Q 2023 compared to $2,916 in 1Q 2022. The EBT of Utah Medical Products, Ltd (Ireland) was EUR 1,962 in 1Q 2023 compared to EUR 1,806 in 1Q 2022. The EBT of Femcare Group Ltd (Femcare Ltd., UK and Femcare Australia Pty Ltd) was GBP 23 in 1Q 2023 compared to GBP (159) in 1Q 2022. The 1Q 2023 EBT of Utah Medical Products Canada, Inc. was CAD 158 in 1Q 2023 compared to CAD 154 in 1Q 2022. </P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Excluding the noncash effects of depreciation, amortization of intangible assets and stock option expense, 1Q 2023 consolidated EBT excluding the remeasured bank balance currency gain or loss and interest expense (&#8220;adjusted consolidated EBITDA&#8221;) were $6,919 compared to $6,371 in 1Q 2022, an 8.6% increase. Management believes that the 1Q 2023 operating performance provides a start that is consistent with achieving its financial objectives for the calendar year 2023, as previously provided in its 2022 SEC 10-K Report. UTMD&#8217;s trailing last twelve-month EBITDA was $28,439. &nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Net Income (NI)</FONT>. </P>
<P style='font:11pt Times New Roman;margin:0'>NI in 1Q 2023 of $4,214 was 19.2% higher than the NI of $3,534 in 1Q 2022. UTMD&#8217;s NI Margin, NI divided by consolidated sales, was 33.7% in 1Q 2023 and 28.7% in 1Q 2022. The average consolidated income tax provision rates (as a % of EBT) in 1Q 2023 was 17.7% and in 1Q 2022 was 22.0%. The lower provision rate in 1Q 2023 resulted primarily from a portion of interest income that is tax-exempt. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'><FONT style='border-bottom:1px solid #000000'>Earnings per share (EPS)</FONT>. &nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'>EPS in 1Q 2023 were 20.2% higher than in 1Q 2022. &nbsp;UTMD&#8217;s increase in NI was leveraged for EPS as a result of 28,629 fewer diluted shares used to calculate EPS in 1Q 2023 compared to 1Q 2022. Diluted shares were 3,636,286 in 1Q 2023 compared to 3,664,915 in 1Q 2022. &nbsp;Outstanding shares were 3,628,067 at the end of 1Q 2023. The number of shares used for calculating EPS was higher than ending shares because of a time-weighted calculation of average outstanding shares plus dilution from unexercised employee and director options. &nbsp;The total number of outstanding unexercised employee and outside director options at March 31, 2023 was 66,883 at an average exercise price of $73.64, including shares awarded but not yet vested. &nbsp;This compares to 67,433 unexercised option shares at the end of 2022 at an average exercise price of $73.66/ share, including shares awarded but not vested. The difference was due to 300 employee option exercises and 250 cancellations during 1Q 2023. The number of shares added as a dilution factor in 1Q 2023 was 8,456 compared to 10,125 in 1Q 2022. </P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Outstanding shares at the end of 1Q 2023 were 3,628,067 compared to 3,627,767 at the end of calendar year 2022. The difference was due to 300 employee option exercises during 1Q 2023.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>There were no stock repurchases in 1Q 2023. &nbsp;During the last year since the end of 1Q 2022, UTMD repurchased 30,105 of its shares. &nbsp;No options were awarded in 1Q 2023. &nbsp;During the last year since the end of 1Q 2022, 20,600 options were awarded to 40 employees at an exercise price of $82.60. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>UTMD paid a $1,070 ($0.295/share) cash dividend to stockholders in 1Q 2023. UTMD did not pay a cash dividend to stockholders in 1Q 2022 because the special $7,309 ($2.00/share) dividend, which was declared in 4Q 2021, was paid in December before the end of the 2021 calendar year instead of in January 2022. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>During 1Q 2023 and 1Q 2022, UTMD did not repurchase its shares. In 2Q 2022, UTMD repurchased 30,105 shares at $82.88 per share. The Company retains the strong desire and financial ability for repurchasing its shares at a price it believes is attractive for remaining stockholders. UTMD&#8217;s closing share price at the end of 1Q 2023 was $94.77, down 6% from the $100.53 closing price at the end of 2022. &nbsp;The closing share price at the end of 1Q 2022 was $89.86. </P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Balance Sheet</FONT>.</P>
<P style='font:11pt Times New Roman;margin:0'>At March 31, 2023 compared to three months earlier at the end of 2022, UTMD&#8217;s cash and investments increased $5.9 million to $80.9 million as a result of profitable operations. At March 31, 2023, net Intangible Assets declined to 17.5% of total consolidated assets from 19.2% on December 31, 2022. Primarily as a result of hedging for supply chain disruption, March 31, 2023 inventories increased another $1.1 million from the end of 2022. The extra raw material purchases helped reduce average inventory turns from 2.7 at the end of 1Q 2022 to 2.0 at the end of 1Q 2023. &nbsp;Because cash and inventories increased substantially while current liabilities remained about the same, UTMD&#8217;s strong current ratio improved to 15.7 at March 31, 2023 from 13.0 at March 31, 2022. &nbsp;Consolidated Accounts Receivable (net of allowances) declined $1.9 million at March 31, 2023 compared to March 31, 2022 as a result of the aging of receivables improving to an average of 27 days on a rolling sales quarter basis compared to 42 days one year ago.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>As of March 31, 2023, Stockholders&#8217; Equity increased $8.8 million compared to a year earlier at March 31, 2022 despite a reduction in Stockholders&#8217; Equity from the $4.2 million ($1.17/ share) in stockholder cash dividends paid during the last twelve months. &nbsp;During 1Q 2023, Stockholders&#8217; Equity increased $3.8 million from the end of 2022.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Financial ratios as of March 31, 2023 which may be of interest to stockholders follow:</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>1)</KBD>Current Ratio = 15.7&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>2)</KBD>Days in Trade Receivables (based on 1Q 2023 sales activity) = 27&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>3)</KBD>Average Inventory Turns (based on 1Q 2023 CGS) = 2.0&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;margin-left:18pt'><KBD style='position:absolute;font:11pt Times New Roman;margin-left:-18pt'>4)</KBD>2023 YTD ROE (before dividends) = 14.5%&nbsp;</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Investors are cautioned that this press release contains forward looking statements and that actual events may differ from those projected. &nbsp;Risk factors that could cause results to differ materially from those projected include global economic conditions, market acceptance of products, regulatory approvals of products, regulatory intervention in current operations, government intervention in healthcare and the economy in general, tax reforms, the Company&#8217;s ability to efficiently manufacture, market and sell products, cybersecurity and foreign currency exchange rates, among other factors that have been and will be outlined in UTMD&#8217;s public disclosure filings with the SEC.</P>
<P style='font:11pt Times New Roman;margin-top:6pt;margin-bottom:0pt'>Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over one hundred countries around the world as the standard for obtaining optimal long term outcomes for their patients. &nbsp;For more information about Utah Medical Products, Inc., visit UTMD&#8217;s website at<B><I> </I></B><FONT style='color:#0000FF;border-bottom:1px solid #0000FF'><B><I>www.utahmed.com</I></B></FONT>.</P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><HR style='page-break-after:always;border:0;height:3pt;background-color:#909090;margin:8pt 0'><P style=line-height:0;margin:0></P>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'><P align=center style='font:12pt Times New Roman;margin:0'><I>Utah Medical Products, Inc.</I></P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;text-indent:4.5pt;margin-left:-18pt'>INCOME STATEMENT, First Quarter ended March 31 </P>
<TABLE style=border-collapse:collapse;margin-left:-17.1pt><TR style=height:40.05pt><TD valign=top style=width:219.6pt><P style='font:11pt Times New Roman;margin:0'>(in thousands except Earnings Per Share)</P>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=bottom style=width:81pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1Q 2023</FONT></P>
</TD><TD valign=bottom style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>1Q 2022</FONT></P>
</TD><TD valign=bottom style=width:83.65pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Percent Change</FONT></P>
</TD></TR>
<TR style=height:14.8pt><TD valign=top style=background-color:#D3F0FE;width:219.6pt><P style='font:11pt Times New Roman;margin:0'>Net Sales</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:81pt><P align=right style='font:11pt Times New Roman;margin:0'>$12,520</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>$12,323</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:83.65pt><P align=right style='font:11pt Times New Roman;margin:0'> 1.6%</P>
</TD></TR>
<TR style=height:14.8pt><TD valign=top style=width:219.6pt><P style='font:11pt Times New Roman;margin:0'>Gross Profit</P>
</TD><TD valign=top style=width:81pt><P align=right style='font:11pt Times New Roman;margin:0'>7,843</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>7,532</P>
</TD><TD valign=top style=width:83.65pt><P align=right style='font:11pt Times New Roman;margin:0'> 4.1%</P>
</TD></TR>
<TR style=height:14.8pt><TD valign=top style=background-color:#D3F0FE;width:219.6pt><P style='font:11pt Times New Roman;margin:0'>Operating Income</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:81pt><P align=right style='font:11pt Times New Roman;margin:0'>4,439</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>4,522</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:83.65pt><P align=right style='font:11pt Times New Roman;margin:0'>(1.9%)</P>
</TD></TR>
<TR style=height:14.8pt><TD valign=top style=width:219.6pt><P style='font:11pt Times New Roman;margin:0'>Income Before Tax</P>
</TD><TD valign=top style=width:81pt><P align=right style='font:11pt Times New Roman;margin:0'>5,119</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>4,530</P>
</TD><TD valign=top style=width:83.65pt><P align=right style='font:11pt Times New Roman;margin:0'>13.0%</P>
</TD></TR>
<TR style=height:14.8pt><TD valign=top style=background-color:#D3F0FE;width:219.6pt><P style='font:11pt Times New Roman;margin:0'>Net Income</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:81pt><P align=right style='font:11pt Times New Roman;margin:0'>4,214</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>3,534</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:83.65pt><P align=right style='font:11pt Times New Roman;margin:0'>19.2%</P>
</TD></TR>
<TR style=height:14.8pt><TD valign=top style=width:219.6pt><P style='font:11pt Times New Roman;margin:0'>Earnings Per Share</P>
</TD><TD valign=top style=width:81pt><P align=right style='font:11pt Times New Roman;margin:0'>$1.159</P>
</TD><TD valign=top style=width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>$0.964</P>
</TD><TD valign=top style=width:83.65pt><P align=right style='font:11pt Times New Roman;margin:0'>20.2%</P>
</TD></TR>
<TR style=height:15.55pt><TD valign=top style=background-color:#D3F0FE;width:219.6pt><P style='font:11pt Times New Roman;margin:0'>Shares Outstanding (diluted)</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:81pt><P align=right style='font:11pt Times New Roman;margin:0'>3,636</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:67.5pt><P align=right style='font:11pt Times New Roman;margin:0'>3,665</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:83.65pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
</TABLE>
<P style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
<P style='font:11pt Times New Roman;margin:0;text-indent:4.5pt;margin-left:-18pt'>BALANCE SHEET</P>
<TABLE style=border-collapse:collapse;margin-left:-15.9pt><TR style=height:21.6pt><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>(in thousands)</P>
</TD><TD valign=top style=width:78.55pt><P align=center style='font:11pt Times New Roman;margin:0'>(unaudited)</P>
<P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>MAR 31, 2023</FONT></P>
</TD><TD valign=top style=width:74.15pt><P align=center style='font:11pt Times New Roman;margin:0'>(audited)</P>
<P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>DEC 31, 2022</FONT></P>
</TD><TD valign=top style=width:78.55pt><P align=center style='font:11pt Times New Roman;margin:0'>(unaudited)</P>
<P align=center style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>MAR 31, 2022</FONT></P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Assets</FONT></P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=background-color:#D3F0FE;width:217.55pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;Cash &amp; Investments</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 80,912</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 75,052</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>$ 65,873</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;Accounts &amp; Other Receivables, Net</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>3,818</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>5,538</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>5,720</P>
</TD></TR>
<TR><TD valign=top style=background-color:#D3F0FE;width:217.55pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;Inventories</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>9,940</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>8,814</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>7,367</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;Other Current Assets</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>442</FONT></P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>515</FONT></P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>520</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#D3F0FE;width:217.55pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>95,112</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>89,919</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>79,480</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Property &amp; Equipment, Net</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>10,241</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>10,224</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>10,997</P>
</TD></TR>
<TR><TD valign=top style=background-color:#D3F0FE;width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Intangible Assets, Net</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>22,417</FONT></P>
</TD><TD valign=top style=background-color:#D3F0FE;width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>23,731</FONT></P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>29,326</FONT></P>
</TD></TR>
<TR style=height:21.15pt><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>$127,770</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>$123,874</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>$119,803</P>
</TD></TR>
<TR><TD valign=top style=background-color:#D3F0FE;width:217.55pt><P style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>Liabilities &amp; Stockholders&#8217; Equity</FONT></P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>&nbsp;</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Accounts Payable</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>1,027</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>1,218</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>1,454</P>
</TD></TR>
<TR><TD valign=top style=background-color:#D3F0FE;width:217.55pt><P style='font:11pt Times New Roman;margin:0'>REPAT Tax Payable</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>419</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>419</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>220</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Other Accrued Liabilities</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4,628</FONT></P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4,323</FONT></P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>4,424</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#D3F0FE;width:217.55pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;Total Current Liabilities</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'> 6,074</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;5,960</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'> &nbsp;6,098</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Deferred Tax Liability &#8211;&nbsp;Intangibles</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>1,456</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>1,513</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>1,946</P>
</TD></TR>
<TR><TD valign=top style=background-color:#D3F0FE;width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Long Term Lease Liability</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>328</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>341</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>382</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Long Term REPAT Tax Payable</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>1,256</P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>1,256</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>1,675</P>
</TD></TR>
<TR><TD valign=top style=background-color:#D3F0FE;width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Deferred Income Taxes</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>638</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>549</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>534</P>
</TD></TR>
<TR><TD valign=top style=width:217.55pt><P style='font:11pt Times New Roman;margin:0'>Stockholders&#8217; Equity</P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>118,018</FONT></P>
</TD><TD valign=top style=width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>114,255</FONT></P>
</TD><TD valign=top style=width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'><FONT style='border-bottom:1px solid #000000'>109,168</FONT></P>
</TD></TR>
<TR><TD valign=top style=background-color:#D3F0FE;width:217.55pt><P style='font:11pt Times New Roman;margin:0'> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities &amp; Stockholders&#8217; Equity</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>$127,770</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:74.15pt><P align=right style='font:11pt Times New Roman;margin:0'>$123,874</P>
</TD><TD valign=top style=background-color:#D3F0FE;width:78.55pt><P align=right style='font:11pt Times New Roman;margin:0'>$119,803</P>
</TD></TR>
</TABLE>
<HR style='border:0;height:0;width:0;margin:14pt 0 0 0'></DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>utmd-20230425_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD9NVDXT]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20230425"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
	<link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
	<link:roleRef roleURI="http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20230425.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:definitionLink xlink:type="extended" xlink:role="http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>utmd-20230425_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD9NVDXT]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20230425"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
	<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
	<link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_LocalPhoneNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Local Phone Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_LocalPhoneNumber' xlink:to='lab_dei_LocalPhoneNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityInteractiveDataCurrent' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Interactive Data Current</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityInteractiveDataCurrent' xlink:to='lab_dei_EntityInteractiveDataCurrent'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementTenderOffer' xlink:to='lab_dei_PreCommencementTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityTaxIdentificationNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Tax Identification Number (TIN)</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityTaxIdentificationNumber' xlink:to='lab_dei_EntityTaxIdentificationNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntitySmallBusiness' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Small Business</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntitySmallBusiness' xlink:to='lab_dei_EntitySmallBusiness'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityPublicFloat' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Public Float</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityPublicFloat' xlink:to='lab_dei_EntityPublicFloat'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressAddressLine1' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Address Line One</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressAddressLine1' xlink:to='lab_dei_EntityAddressAddressLine1'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:label xlink:type='resource' xlink:label='lab_us-gaap_TextBlockAbstract' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Details</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='us-gaap_TextBlockAbstract' xlink:to='lab_us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressCityOrTown' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, City or Town</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressCityOrTown' xlink:to='lab_dei_EntityAddressCityOrTown'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_PreCommencementIssuerTenderOffer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Pre-commencement Issuer Tender Offer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_PreCommencementIssuerTenderOffer' xlink:to='lab_dei_PreCommencementIssuerTenderOffer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentType' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>SEC Form</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentType' xlink:to='lab_dei_DocumentType'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityEmergingGrowthCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Emerging Growth Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityEmergingGrowthCompany' xlink:to='lab_dei_EntityEmergingGrowthCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_WrittenCommunications' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Written Communications</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_WrittenCommunications' xlink:to='lab_dei_WrittenCommunications'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SecurityExchangeName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Exchange</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SecurityExchangeName' xlink:to='lab_dei_SecurityExchangeName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_TradingSymbol' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Trading Symbol</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_TradingSymbol' xlink:to='lab_dei_TradingSymbol'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityRegistrantName' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant Name</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityRegistrantName' xlink:to='lab_dei_EntityRegistrantName'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressStateOrProvince' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, State or Province</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressStateOrProvince' xlink:to='lab_dei_EntityAddressStateOrProvince'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentDescription' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Description</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentDescription' xlink:to='lab_dei_AmendmentDescription'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityExTransitionPeriod' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Ex Transition Period</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityExTransitionPeriod' xlink:to='lab_dei_EntityExTransitionPeriod'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CurrentFiscalYearEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Fiscal Year End</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CurrentFiscalYearEndDate' xlink:to='lab_dei_CurrentFiscalYearEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_AmendmentFlag' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Amendment Flag</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_AmendmentFlag' xlink:to='lab_dei_AmendmentFlag'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_CityAreaCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>City Area Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_CityAreaCode' xlink:to='lab_dei_CityAreaCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityIncorporationStateCountryCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Incorporation, State or Country Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityIncorporationStateCountryCode' xlink:to='lab_dei_EntityIncorporationStateCountryCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCurrentReportingStatus' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Current with reporting</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCurrentReportingStatus' xlink:to='lab_dei_EntityCurrentReportingStatus'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCommonStockSharesOutstanding' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Number of common stock shares outstanding</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCommonStockSharesOutstanding' xlink:to='lab_dei_EntityCommonStockSharesOutstanding'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_SolicitingMaterial' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Soliciting Material</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_SolicitingMaterial' xlink:to='lab_dei_SolicitingMaterial'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityAddressPostalZipCode' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity Address, Postal Zip Code</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityAddressPostalZipCode' xlink:to='lab_dei_EntityAddressPostalZipCode'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityCentralIndexKey' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Registrant CIK</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityCentralIndexKey' xlink:to='lab_dei_EntityCentralIndexKey'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFileNumber' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Entity File Number</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFileNumber' xlink:to='lab_dei_EntityFileNumber'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityFilerCategory' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Filer Category</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityFilerCategory' xlink:to='lab_dei_EntityFilerCategory'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityWellKnownSeasonedIssuer' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Well-known Seasoned Issuer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityWellKnownSeasonedIssuer' xlink:to='lab_dei_EntityWellKnownSeasonedIssuer'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_DocumentPeriodEndDate' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Period End date</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_DocumentPeriodEndDate' xlink:to='lab_dei_DocumentPeriodEndDate'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityShellCompany' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Shell Company</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityShellCompany' xlink:to='lab_dei_EntityShellCompany'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:label xlink:type='resource' xlink:label='lab_dei_EntityVoluntaryFilers' xlink:role='http://www.xbrl.org/2003/role/label' xml:lang='en-US'>Voluntary filer</link:label>
		<link:labelArc order='1.0' xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/concept-label' xlink:from='dei_EntityVoluntaryFilers' xlink:to='lab_dei_EntityVoluntaryFilers'/>
	</link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>utmd-20230425_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD9NVDXT]. www.edgarsuite.com -->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase"
		xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
		xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"
		xmlns:fil="http://utahmed.com/20230425"
		xmlns:link="http://www.xbrl.org/2003/linkbase"
		xmlns:xlink="http://www.w3.org/1999/xlink"
		xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
		xmlns:xbrli="http://www.xbrl.org/2003/instance">
	<link:roleRef roleURI="http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation" xlink:type="simple" xlink:href="utmd-20230425.xsd#idr_DocumentDocumentAndEntityInformation"/>
	<link:presentationLink xlink:type="extended" xlink:role="http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation">
		<link:loc xlink:type='locator' xlink:href='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TextBlockAbstract' xlink:label='us-gaap_TextBlockAbstract'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityCentralIndexKey' xlink:label='dei_EntityCentralIndexKey'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCentralIndexKey' use='optional' order='1.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_CurrentFiscalYearEndDate' xlink:label='dei_CurrentFiscalYearEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CurrentFiscalYearEndDate' use='optional' order='2.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityRegistrantName' xlink:label='dei_EntityRegistrantName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityRegistrantName' use='optional' order='3.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_DocumentType' xlink:label='dei_DocumentType'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentType' use='optional' order='4.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_DocumentPeriodEndDate' xlink:label='dei_DocumentPeriodEndDate'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_DocumentPeriodEndDate' use='optional' order='5.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_TradingSymbol' xlink:label='dei_TradingSymbol'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_TradingSymbol' use='optional' order='6.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_SecurityExchangeName' xlink:label='dei_SecurityExchangeName'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SecurityExchangeName' use='optional' order='7.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityTaxIdentificationNumber' xlink:label='dei_EntityTaxIdentificationNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityTaxIdentificationNumber' use='optional' order='8.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityCommonStockSharesOutstanding' xlink:label='dei_EntityCommonStockSharesOutstanding'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCommonStockSharesOutstanding' use='optional' order='9.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityPublicFloat' xlink:label='dei_EntityPublicFloat'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityPublicFloat' use='optional' order='10.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityFilerCategory' xlink:label='dei_EntityFilerCategory'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFilerCategory' use='optional' order='11.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityCurrentReportingStatus' xlink:label='dei_EntityCurrentReportingStatus'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityCurrentReportingStatus' use='optional' order='12.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityInteractiveDataCurrent' xlink:label='dei_EntityInteractiveDataCurrent'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityInteractiveDataCurrent' use='optional' order='13.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityVoluntaryFilers' xlink:label='dei_EntityVoluntaryFilers'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityVoluntaryFilers' use='optional' order='14.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityWellKnownSeasonedIssuer' xlink:label='dei_EntityWellKnownSeasonedIssuer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityWellKnownSeasonedIssuer' use='optional' order='15.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityShellCompany' xlink:label='dei_EntityShellCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityShellCompany' use='optional' order='16.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntitySmallBusiness' xlink:label='dei_EntitySmallBusiness'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntitySmallBusiness' use='optional' order='17.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityEmergingGrowthCompany' xlink:label='dei_EntityEmergingGrowthCompany'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityEmergingGrowthCompany' use='optional' order='18.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityExTransitionPeriod' xlink:label='dei_EntityExTransitionPeriod'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityExTransitionPeriod' use='optional' order='19.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_AmendmentDescription' xlink:label='dei_AmendmentDescription'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentDescription' use='optional' order='20.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityIncorporationStateCountryCode' xlink:label='dei_EntityIncorporationStateCountryCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityIncorporationStateCountryCode' use='optional' order='21.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityFileNumber' xlink:label='dei_EntityFileNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityFileNumber' use='optional' order='22.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityAddressAddressLine1' xlink:label='dei_EntityAddressAddressLine1'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressAddressLine1' use='optional' order='23.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityAddressCityOrTown' xlink:label='dei_EntityAddressCityOrTown'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressCityOrTown' use='optional' order='24.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityAddressStateOrProvince' xlink:label='dei_EntityAddressStateOrProvince'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressStateOrProvince' use='optional' order='25.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_EntityAddressPostalZipCode' xlink:label='dei_EntityAddressPostalZipCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_EntityAddressPostalZipCode' use='optional' order='26.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_CityAreaCode' xlink:label='dei_CityAreaCode'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_CityAreaCode' use='optional' order='27.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_LocalPhoneNumber' xlink:label='dei_LocalPhoneNumber'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_LocalPhoneNumber' use='optional' order='28.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_WrittenCommunications' xlink:label='dei_WrittenCommunications'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_WrittenCommunications' use='optional' order='29.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_SolicitingMaterial' xlink:label='dei_SolicitingMaterial'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_SolicitingMaterial' use='optional' order='30.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_PreCommencementTenderOffer' xlink:label='dei_PreCommencementTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementTenderOffer' use='optional' order='31.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_PreCommencementIssuerTenderOffer' xlink:label='dei_PreCommencementIssuerTenderOffer'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_PreCommencementIssuerTenderOffer' use='optional' order='32.0'/>
		<link:loc xlink:type='locator' xlink:href='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd#dei_AmendmentFlag' xlink:label='dei_AmendmentFlag'/>
		<link:presentationArc xlink:type='arc' xlink:arcrole='http://www.xbrl.org/2003/arcrole/parent-child' xlink:from='us-gaap_TextBlockAbstract' xlink:to='dei_AmendmentFlag' use='optional' order='33.0'/>
	</link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>utmd-20230425.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='iso-8859-1'?>
<!-- Produced by EDGARsuite software, Advanced Computer Innovations, Inc., Copyright (C) 2008-2023 [PPXK5GW761L0VD9NVDXT]. www.edgarsuite.com -->
<schema xmlns:cef='http://xbrl.sec.gov/cef/2022' xmlns='http://www.w3.org/2001/XMLSchema' xmlns:fil='http://utahmed.com/20230425' xmlns:dei='http://xbrl.sec.gov/dei/2022q4' xmlns:xlink='http://www.w3.org/1999/xlink' xmlns:xbrldt='http://xbrl.org/2005/xbrldt' targetNamespace='http://utahmed.com/20230425' xmlns:link='http://www.xbrl.org/2003/linkbase' xmlns:xbrli='http://www.xbrl.org/2003/instance' elementFormDefault='qualified' attributeFormDefault='unqualified'>
	<annotation>
		<appinfo>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20230425_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20230425_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:linkbaseRef xlink:type="simple" xlink:href="utmd-20230425_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
			<link:roleType roleURI="http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation" id="idr_DocumentDocumentAndEntityInformation">
				<link:definition>000010 - Document - Document and Entity Information</link:definition>
				<link:usedOn>link:presentationLink</link:usedOn>
				<link:usedOn>link:definitionLink</link:usedOn>
				<link:usedOn>link:calculationLink</link:usedOn>
			</link:roleType>
		</appinfo>
	</annotation>
	<import schemaLocation='http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd' namespace='http://www.xbrl.org/2003/instance'/>
	<import schemaLocation='http://www.xbrl.org/2005/xbrldt-2005.xsd' namespace='http://xbrl.org/2005/xbrldt'/>
	<import schemaLocation='https://www.xbrl.org/dtr/type/2020-01-21/types.xsd' namespace='http://www.xbrl.org/dtr/type/2020-01-21'/>
	<import namespace='http://xbrl.sec.gov/dei/2022q4' schemaLocation='https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd'/>
	<import namespace='http://fasb.org/us-gaap/2022' schemaLocation='https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd'/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140590246204544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 25, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Registrant CIK</a></td>
<td class="text">0000706698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">UTAH MEDICAL PRODUCTS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">SEC Form</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Period End date</a></td>
<td class="text">Apr. 25,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Tax Identification Number (TIN)</a></td>
<td class="text">87-0342734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-12575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7043 South 300 West<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Midvale<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">566-1200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>utmd-20230425_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022q4"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="utmd-20230425.xsd" xlink:type="simple"/>
    <context id="D230425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000706698</identifier>
        </entity>
        <period>
            <startDate>2023-04-25</startDate>
            <endDate>2023-04-25</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="D230425" id="fact1">0000706698</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="D230425" id="fact2">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="D230425">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="D230425">2023-04-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="D230425">UTAH MEDICAL PRODUCTS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D230425">UT</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="D230425">000-12575</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="D230425">87-0342734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D230425">7043 South 300 West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="D230425">Midvale</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="D230425">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="D230425">84047</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D230425">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D230425">566-1200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="D230425">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="D230425">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="D230425">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="D230425">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="D230425">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ .("95I>*NQS     $P(   L
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MEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( #B
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( #B F5:%Q[[\X@,  )<.   8
M          " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    "  X@)E6GZ ;\+$"  #B#   #0              @ $F#   >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( #B F5:7BKL<P    !,"   +
M  "  0(/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( #B F58<.&7J/P$  #P"
M   /              "  >L/  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M"  X@)E6)!Z;HJT   #X 0  &@              @ %7$0  >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  X@)E699!YDAD!  #/ P
M$P              @ $\$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
.."0 ) #X"  "&$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>19</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="utmd-20230425.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000010 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="utmd-20230425.htm">utmd-20230425.htm</File>
    <File>utmd-20230425.xsd</File>
    <File>utmd-20230425_def.xml</File>
    <File>utmd-20230425_lab.xml</File>
    <File>utmd-20230425_pre.xml</File>
    <File>utmd_ex99z1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="19">http://xbrl.sec.gov/dei/2022q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "utmd-20230425.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022q4": 19
   },
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "utmd-20230425_def.xml"
     ]
    },
    "inline": {
     "local": [
      "utmd-20230425.htm"
     ]
    },
    "labelLink": {
     "local": [
      "utmd-20230425_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "utmd-20230425_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "utmd-20230425.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd"
     ]
    }
   },
   "elementCount": 34,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 19,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "fil",
   "nsuri": "http://utahmed.com/20230425",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230425.htm",
      "contextRef": "D230425",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000010 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "utmd-20230425.htm",
      "contextRef": "D230425",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Fiscal Year End"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Period End date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "SEC Form"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Registrant CIK"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Number of common stock shares outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Current with reporting"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Tax Identification Number (TIN)"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Voluntary filer"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Trading Exchange"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://utahmed.com/20230425/role/idr_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_TextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Details"
       }
      }
     },
     "localname": "TextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001096906-23-000901-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001096906-23-000901-xbrl.zip
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MER<]86M 4*!Y5X=?Y( 6HD=._E<&Y=]02P,$%     @ .("95H]K(, B"
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M"0G:OF_3FAS.9]\0X<83SWJB:XTI,Q>!5:EZTI_3:K=9*@!!BMC*[.?\U1-
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MM>OCV5Y^P/PQ_]!RMO<O4$L#!!0    ( #B F5:=DE8O,2$  ,6^   /
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MR3#BB/*#9)@5P\K *HG\C/G$-@NAU0+%2G'58GA4?,=-Z/<P'9*3NX0@2?6
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MO@UK1RIC:X[I[,@6-,&I7'*NM??5U-J%4/D>+<%%5HF[;W'O:)W&F@F$]<7
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MOGQ^_\/_ E!+ 0(4 Q0    ( #B F59E?T;F:PX  ,YI   1
M  "  0    !U=&UD+3(P,C,P-#(U+FAT;5!+ 0(4 Q0    ( #B F59#H !Z
MX0(  $()   1              "  9H.  !U=&UD+3(P,C,P-#(U+GAS9%!+
M 0(4 Q0    ( #B F5;Q^[%4%P(  "8'   5              "  :H1  !U
M=&UD+3(P,C,P-#(U7V1E9BYX;6Q02P$"% ,4    "  X@)E6CVL@P"((  !6
M3P  %0              @ 'T$P  =71M9"TR,#(S,#0R-5]L86(N>&UL4$L!
M A0#%     @ .("95CA0"GZM!0  RC0  !4              ( !21P  '5T
M;60M,C R,S T,C5?<')E+GAM;%!+ 0(4 Q0    ( #B F5:=DE8O,2$  ,6^
M   /              "  2DB  !U=&UD7V5X.3EZ,2YH=&U02P4&      8
,!@"$ 0  AT,

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
